Target: LGI1
Conjugate: ATTO 390
Product Type: Monoclonal
Clone Number: N283/7 (Formerly sold as S283-7)
Immunogen: Fusion protein amino acids 37-113 (LRRNT domain and first LRR repeat) of mouse LGI1. Rat: 100% identity (77/77 amino acids identical). Human: 98% identity (76/77 amino acids identical). ~50% identity with LGI2, LGI3 and LGI4.
Swiss-Prot: Q9JIA1.1
Purification: Protein G Purified
Storage Buffer: PBS pH 7.4, 50% glycerol, 0.1% sodium azide *Storage buffer may change when conjugated
Concentration: 1 mg/ml
Specificity: Detects ~60kDa.
Cellular Localization: Cell Junction,Golgi Apparatus,Endoplasmic Reticulum
Scientific Background: The leucine-rich, glioma inactivated gene 1 (LGI1) was first identified as a candidate tumor suppressor gene for glioma and may play a role in other cancers. LGI1 is a member of a family of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 serves as a ligand to ADAM22, a metalloprotease localized at the synapse. Mutations in LGI1 account for nearly half of autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Two isoforms of LGI1 are known to exist; this LGI1 antibody will recognize only the longer form.
References: 1. Chernova O.B., Somerville R.P. and Cowell J.K. (1998) Oncogene. 17:2873-81.2. Fialka F., et al. (2008) Oral Oncol. 3. Gu W., et al. (2005) Mol. Biol. Evol. 22:2209-16.4. Fukata Y., et al. (2006) Science. 313:1792-5.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
English
Deutsch
